Abbreviated Name

Pancreatic Ref Set App: Honda (2014)

Lead Investigator

Honda, Kazufumi — Nippon Medical School

Coordinating Investigator

Zheng, Yingye — Fred Hutchinson Cancer Center

Involved Investigators

• Honda, Kazufumi — Nippon Medical School
• Zheng, Yingye — Fred Hutchinson Cancer Center

Abstract

See objectives

Aims

To improve the survival rate of pancreatic cancer, non-invasive diagnostic methods that detect the disease in its early stage must be developed.

Analytic Method

The National Cancer Institute (NCI) will send the pancreatic cancer reference serum samples to the National Cancer Center, and the National Cancer Center (NCC) will then blindly measure the levels of apoAII isoforms in the reference samples. NCC will return the data obtained from the reference set, and the NCI will subsequently calculate sensitivity, specificity, and the AUC. In addition, the NCI will evaluate the clinical utility for early detection of pancreatic cancer

Outcome

See objectives

Publications

• Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms.

Biomarkers

• ApoAII-ATQ/AT
• AT
• ATQ
• CA19-9

Data Collections

• No data collections available at this time for this protocol.

Start Date

Aug 26 2014

Estimated Finish Date

Aug 25 2015

Finish Date

Feb 18 2015

Protocol ID

392

Protocol Type

Reference Set

Fields of Research

• Proteomics

Collaborative Group

G.I. and Other Associated Cancers Research Group

Cancer Types

• Malignant neoplasm of pancreas

Phased Status

1